Date: 2012-08-14
Type of information: Distribution agreement
Compound: xeno-free mesenchymal stem cell differentiation media
Company: Plasticell (UK) EMD Millipore (USA), the Life Science Division of Merck KGaA (Germany)
Therapeutic area: Technology - Services
Type agreement: licensing
distribution
Action mechanism:
Disease:
Details: Plasticell, the UK stem cell differentiation specialist has licensed EMD Millipore, the Life Science Division of Merck KGaA, to distribute a single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®. The optimized osteogenic medium was developed using CombiCult® to perform a rapid screen of 3,375 combinations of fully defined cell culture media, equivalent to hundreds of thousands of combinations of media components.
This osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the terms of the contract, EMD Millipore has secured a license to distribute the medium globally for research purposes with Plasticell retaining full rights over therapeutic applications. Plasticell’s medium will be available for research purposes from EMD Millipore in Q3 2012 and available now for commercial applications directly from Plasticell.
Financial terms:
Latest news:
